The efficacy of anti-TNF-α antibodies including infliximab and adalimumab for refractory intestinal Behcet's disease has recently been demonstrated in a series of case reports. The efficacy of switching to a different kind of anti-TNF-α agent in the face of refractoriness to one kind of anti-TNF-α agent, a common practice of proven efficacy in rheumatoid arthritis, has yet not been reported for intestinal Behcet's disease. In the present study, we report a case of 52-year-old female patient with intestinal Behcet's disease, who lost initial good response to infliximab, and was refractory to subsequent administrations of adalimumab. Her recent relapse of intestinal lesions could be successfully treated with etanercept. This case suggests that switching to etanercept might be a reasonable therapeutic option in case of intestinal Behcet's disease with secondary non-response to anti-TNF-α antibodies that is most likely to be mediated by anti-drug antibody.
Introduction
Intestinal Behcet's disease is a potentially life-threatening manifestation of Behcet`s disease, because refractoriness to conventional treatment such as glucocorticoid, azathioprine and thalidomide can lead to complications including bleeding and perforation resulting in high rates of morbidity and mortality.
Recently, there have been a series of case reports on successful use of anti-TNF-α antibodies including infliximab and adalimumab in the induction and maintenance of the remission of refractory intestinal Behcet's disease (1) . However, a high rate of recurrence is another difficult aspect of intestinal Behcet's disease, with a reported recurrence rate of 75% in two years in a small group of surgically-treated Behcet's disease patients (2) . Therefore, although the exact rates remain obscure, refractoriness to one kind of anti-TNF-α agent may occur throughout the course of treatment. In the case of rheumatoid arthritis, one area in which anti-TNF-α agents are most widely and successfully used for the treatment, switching to a different kind of anti-TNF-α agent is a common and effective way of dealing with refractoriness to an anti-TNF-α agent (3) . In this report, we describe a case of intestinal Behcet's disease that showed a loss of initial good response to infliximab and resistence to subsequent adalimumab, in which switching to etanercept resulted in healing of intestinal ulcers.
Case Report
A 52-year-old female patient with known intestinal Behcet's disease presented to a rheumatology outpatient clinic with a complaint of aggravated abdominal pain for the last two weeks. Pain was most severe on the right upper and lower quadrant of the abdomen. There was no history of hematochezia. The patient has recently been on prednisolone 7.5 mg, azathioprine 100 mg once a day. There was mild tenderness on the right upper and lower quadrant of the abdomen. ESR and CRP rose to 52 mm/hr and 2.60 mg/dL, respectively, which were within normal range on the last follow-up three months ago. On colonofiberscopy, there was a huge ulcer on the terminal ileum and ileocecal (IC) valve, with surrounding In the case of rheumatoid arthritis, the response to a second anti-TNF-α agent is known to be related to the reason for the failure of the first anti-TNF-α agent. According to the data from British Society of Rheumatology Biologics Register, although the drug survival after switching was favorable with a 6 month-drug survival rate of more than 70%, patients who failed a first agent due to inefficacy were more likely to fail to respond to a second agent due to inefficacy (3). In accordance with this finding, the UK National Institute for Health and Clinical Excellence (NICE) guidance recommends considering switching to another anti-TNF-α agent only when adverse events are the reason for discontinuation (6) .
Recently it has was shown that the different causes of initial no response to a anti-TNF-α agent have different implications on the response to subsequent anti-TNF-α treatment. Non-responders to infliximab due to immunogenicity (formation of anti-drug antibodies) had a response rate equivalent to that in TNF-naïve group in response to subsequent treatment with adalimumab or etanercept (7, 8) . According to these findings, etanercept could be a good alternative agent in face of inefficacy due to immunogenicity, because etanercept is known to be associated with minimal formation of anti-drug antibodies (9) . Therefore, although anti-drug antibody could not be measured, switching to etanercept was a rational option in this case because a secondary loss of response due to anti-drug antibodies was the most likely cause of the secondary non-response to infliximab and subsequent adalimumab.
One of interesting aspects of this case is that intestinal manifestation of Behcet's disease responded to etanercept that has not been shown to be effective in Crohn`s disease, in contrast to the other anti-TNF-α agents (10) . 
Summary
This case suggests that switching to etanercept might be a reasonable therapeutic option in intestinal Behcet's disease with secondary non-response to anti-TNF-α antibodies such as infliximab and adalimumab. This concept needs to be proved in a larger number of cases.
